Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

28 Applying Pharmacogenomics in Therapeutics
78. Schackman, B.R., et al. The cost-effectiveness of HLA-B*5701 genetic screening to
guide initial antiretroviral therapy for HIV. AIDS, 2008; 22: 2025–33.
79. Lalonde, R.G., et al. Successful implementation of a national HLA-B85701 genetic testing
service in Canada. Tissue Antigens, 2009; 75: 12–18.
80. Shah, J. Criteria influencing the clinical uptake of pharmacogenomic strategies. BMJ,
2004; 328: 1482.
81. Kaniwa, N., et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-
Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia,
2010; 51(12): 2461–5.
82. Gomes, E.R. and P. Demoly. Epidemiology of hypersensitivity drug reactions. Curr
Opin Allergy Clin Immunol, 2005; 5(4): 309–16.
83. Rzany, B., et al. Histopathological and epidemiological characteristics of patients with
erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal
necrolysis. Br J Dermatol, 1996; 135(1): 6–11.
84. Roujeau, J.C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis:
A clinical classification. J Invest Dermatol, 1994; 102(6): 28S–30S.
85. McCormack, M., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity
reactions in Europeans. N Engl J Med, 2011; 364(12): 1134–43.
86. Ozeki, T., et al. Genome-wide association study identifies HLA-A*3101 allele as a
genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in
Japanese population. Hum Mol Genet, 2011; 20(5): 1034–41.
87. Edwards, S.G., et al. Concordance of primary generalised epilepsy and carbamazepine
hypersensitivity in monozygotic twins. Postgrad Med J, 1999; 75(889): 680–1.
88. Mauri-Hellweg, D., et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals
allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol, 1995;
155(1): 462–72.
89. Hung, S.I., et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse
drug reactions. Pharmacogenet Genomics, 2006; 16(4): 297–306.
90. Aihara, M. Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol, 2011;
38(3): 246–54.
91. Naisbitt, D.J., et al. Hypersensitivity reactions to carbamazepine: Characterization
of the specificity, phenotype, and cytokine profile of drug-specific T cell clones.
Mol Pharmacol, 2003; 63(3): 732–41.
92. Lee, M.T., et al. Pharmacogenetics of toxic epidermal necrolysis. Expert Opin
Pharmacother, 2010; 11(13): 2153–62.
93. Lonjou, C., et al. A marker for Stevens-Johnson syndrome …: Ethnicity matters.
Pharmacogenomics J, 2006; 6(4): 265–8.
94. Schawartz, J. and A. Pollack. Judge invalidates human gene patent. The New York
Times, 2010. Available from: http://www.nytimes.com/2010/03/30/business/30gene.
html (accessed December 2, 2011).
95. Makmor-Bakry, M., et al. Genetic variants in microsomal epoxide hydrolase influence
carbamazepine dosing. Clin Neuropharmacol, 2009; 32(4): 205–12.
96. Alfirevic, A., et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity.
Pharmacogenomics, 2006; 7(6): 813–18.
97. Chung, W.H., et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature,
2004; 428(6982): 486.
98. Chen, P., et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in
Taiwan. N Engl J Med, 2011; 364(12): 1126–33.
99. Tassaneeyakul, W., et al. Association between HLA-B*1502 and carbamazepineinduced
severe cutaneous adverse drug reactions in a Thai population. Epilepsia, 2010;
51(5): 926–30.